RQ Bio secures $115m to develop influenza antibody programme

​RQ Bio has closed a $115m Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups.

The post RQ Bio secures $115m to develop influenza antibody programme appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.